An Observational Study on Sarilumab-exposed Pregnancies

Inclusion criteria: * Cohort 1: Sarilumab-Exposed Cohort * Currently pregnant, exposed to Kevzara (sarilumab) for approved indication * Cohort 2: Disease-matched Comparison Cohort * Currently pregnant, diagnosed with Kevzara (sarilumab) approved indication * Cohort 3: Non-diseased Comparison Cohort * Currently pregnant, not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara Exclusion criteria: First contact the Registry after prenatal diagnosis of any major structural defect or after pregnancy outcome is known (retrospective data). Enrolled in this cohort study with a previous pregnancy. Cohort 1: Sarilumab-Exposed Cohort * Exposed to Kevzara (sarilumab) for an indication other than a currently approved indication. * Exposure to another biologic during pregnancy or within 10 weeks prior to the first day of LMP. * Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy. * Cohort 2: Disease-matched Comparison Cohort * Exposure to any Kevzara (sarilumab) during pregnancy or within 10 weeks prior to the first day of the LMP. * Exposed to methotrexate, cyclophosphamide, chlorambucil, or mycophenolate mofetil in pregnancy (ie, at any time after the LMP), or leflunomide within two years prior to pregnancy unless a blood level for leflunomide below 0.02 mcg/mL has been documented prior to LMP before the pregnancy. * Cohort 3: Non-diseased Comparison Cohort * Diagnosed for any serious chronic disease that is thought to adversely impact pregnancy. * Exposed to a known human teratogen during pregnancy as confirmed by the OTIS Research Center The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.